Regeneron completes acquisition of checkmate pharmaceuticals

Acquisition strengthens regeneron's innovative portfolio of immuno-oncology candidates and diversified approach to cancer treatment tarrytown, n.y. , may 31, 2022 /prnewswire/ -- regeneron pharmaceuticals, inc. (nasdaq: regn) today announced that it has successfully acquired checkmate pharmaceuticals, inc., deepening its commitment to immuno-oncology and adding a new modality to the company's portfolio of potential combination-ready approaches for difficult-to-treat cancers.
REGN Ratings Summary
REGN Quant Ranking